These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11964299)

  • 1. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
    von Bergwelt-Baildon MS; Vonderheide RH; Maecker B; Hirano N; Anderson KS; Butler MO; Xia Z; Zeng WY; Wucherpfennig KW; Nadler LM; Schultze JL
    Blood; 2002 May; 99(9):3319-25. PubMed ID: 11964299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells.
    Mathieu M; Cotta-Grand N; Daudelin JF; Boulet S; Lapointe R; Labrecque N
    PLoS One; 2012; 7(1):e30139. PubMed ID: 22291907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
    Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
    J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells.
    Anderson KS; Zeng W; Sasada T; Choi J; Riemer AB; Su M; Drakoulakos D; Kang YJ; Brusic V; Wu C; Reinherz EL
    Cancer Immunol Immunother; 2011 Jun; 60(6):857-67. PubMed ID: 21400024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel immunotherapy to hepatocellular carcinoma: CD40-activated B lymphocytes transfected with AFPmRNA.
    Wan Y; Ma X; Li X; Yi J
    Med Hypotheses; 2009 Nov; 73(5):835-7. PubMed ID: 19632790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
    Carpenter EL; Mick R; Rüter J; Vonderheide RH
    J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
    Van den Bosch GA; Ponsaerts P; Nijs G; Lenjou M; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Clin Exp Immunol; 2005 Mar; 139(3):458-67. PubMed ID: 15730391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
    Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
    J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens.
    Kim SK; Nguyen Pham TN; Nguyen Hoang TM; Kang HK; Jin CJ; Nam JH; Chung SY; Choi SJ; Yang DH; Kim YK; Chung IJ; Kim HJ; Lee JJ
    Ann Hematol; 2009 Nov; 88(11):1113-23. PubMed ID: 19277657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.
    Shimabukuro-Vornhagen A; Draube A; Liebig TM; Rothe A; Kochanek M; von Bergwelt-Baildon MS
    J Exp Clin Cancer Res; 2012 May; 31(1):47. PubMed ID: 22592077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
    Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.
    Coughlin CM; Vance BA; Grupp SA; Vonderheide RH
    Blood; 2004 Mar; 103(6):2046-54. PubMed ID: 14630810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40-activated B cells induce anti-tumor immunity in vivo.
    Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.
    Rossetti RAM; Lorenzi NPC; Yokochi K; Rosa MBSF; Benevides L; Margarido PFR; Baracat EC; Carvalho JP; Villa LL; Lepique AP
    PLoS One; 2018; 13(7):e0199034. PubMed ID: 29975708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow.
    Jin Y; Fuller L; Ciancio G; Burke GW; Tzakis AG; Ricordi C; Miller J; Esquenzai V
    Hum Immunol; 2004 Feb; 65(2):93-103. PubMed ID: 14969764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient generation of antigen-specific CTLs by the BAFF-activated human B Lymphocytes as APCs: a novel approach for immunotherapy.
    Yiwen Z; Shilin G; Yingshi C; Lishi S; Baohong L; Chao L; Linghua L; Ting P; Hui Z
    Oncotarget; 2016 Nov; 7(47):77732-77748. PubMed ID: 27780916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.